AstraZeneca PLC (AZN)vsDanaher Corporation (DHR)
AZN
AstraZeneca PLC
$169.51
+2.88%
HEALTHCARE · Cap: $263.78B
DHR
Danaher Corporation
$236.95
+1.24%
HEALTHCARE · Cap: $161.01B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 144% more annual revenue ($61.37B vs $25.11B). AZN leads profitability with a 17.0% profit margin vs 16.0%. AZN appears more attractively valued with a PEG of 1.22. DHR earns a higher WallStSmart Score of 66/100 (B-).
AZN
Buy62
out of 100
Grade: C+
DHR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Intrinsic value data unavailable for DHR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 59.7% YoY
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio. A P/E of 40.8x leaves little room for execution misses.
Key Dynamics to Monitor
DHR carries more volatility with a beta of 0.80 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (66/100 vs 62/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?